CDIO · Cardio Diagnostics Holdings, Inc.
$1.56
-0.06 (-3.70%)
At close · Jul 28
Market Cap
$4.79M
Shares
2.96M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$14.83K
-57.5%
FY2025
Net Income
-$6.5M
+22.5%
FY2025
Operating Margin
-43737.46%
-19759.6pp
FY2025
Diluted EPS
-$3.71
+60.3%
FY2025
Operating Cash Flow
-$5.73M
-14.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $16.57K | $14.83K | $34.89K | $17.07K | $950 | $901 | |
| $652.2K | $641.21K | $227.97K | $145.18K | $40.45K | $31.47K | |
| — | $766.89K | $1.23M | $158.51K | $92.7K | $103.32K | |
| — | $5.03M | $6.92M | $6.94M | $4.4M | $470.56K | |
| — | $5333 | $16K | $16K | $16K | — | |
| — | $65.23K | $19.74K | $19.18K | $16K | $16K | |
| $6.65M | $6.5M | $8.4M | $7.26M | $4.55M | $621.35K | |
| -$6.64M | -$6.48M | -$8.37M | -$7.24M | -$4.55M | -$620.45K | |
| — | -43737.46% | -23977.86% | -42440.43% | -478784.32% | -68862.15% | |
| — | -$6.42M | -$8.35M | -$7.22M | -$4.53M | -$604.45K | |
| $13.55K | $14.8K | $18.64K | $6.74M | — | — | |
| -$12.91K | -$14.09K | -$17.58K | -$1.13M | -$112.53K | — | |
| -$6.65M | -$6.5M | -$8.38M | -$8.38M | -$4.66M | -$620.45K | |
| $0 | — | — | — | $0 | $0 | |
| -$6.65M | -$6.5M | -$8.38M | -$8.38M | -$4.66M | -$620.45K | |
| — | -43832.49% | -24028.24% | -49087.81% | -490630% | -68862.15% | |
| — | — | — | — | $4.66M | $620.45K | |
| USD/shares | — | -$3.71 | -$9.35 | -$19.80 | -$45.30 | -$15.90 |
| USD/shares | — | -$3.71 | -$9.35 | -$19.80 | -$45.30 | -$15.90 |
| shares | — | 1.75M | 896.42K | 422.84K | 102.92K | 38.77K |
| shares | — | 1.75M | 896.42K | 422.84K | 102.92K | 38.77K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 153 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segments | $14,825 | $34,890 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Product Test Sales | $14,825 | $34,890 |